Neuropathology Flashcards

(45 cards)

1
Q

Describe the differences of necrosis and apoptosis:

A

Necrosis is cell murder (physical or chemical injury from which the cell cannot recover).
Apoptosis is cell suicide (self-destruct programme, active process requiring energy and sometimes new gene expression).
Distinguished by different biochemical and morphological characteristics.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List the properties of necrosis:

A
Sudden, severe death
Passive process - no energy required
Membrane disintegrates and cell becomes leaky
Cell and organelle swelling
Dispersal of chromatin and random DNA fragmentation
Cell lysis
Inflammatory response
No new gene expression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

List the properties of apoptosis:

A
Subtle, slowly evolving cell death
Active process - energy required
Membrane blebbing
Cell shrinks, organelles remain intact
Chromatin condenses, internucleosomal DNA fragmentation (regular 180 bp pattern)
Apoptotic bodies engulfed by phagocytes
No inflammatory response
New gene expression often required
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe why apoptosis is important:

A

Important for morphogenesis of embyronic tissue
Physiological mechanism for regulation of cell numbers - homeostasis of adult organs and tissues
Eliminates cells that are damaged, infected or in the wrong place

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the importance of neuronal apoptosis:

A

Neuronal apoptosis is important for development of the CNS and PNS.
Approximately half the neurons generated in the mammalian nervous system are removed by apoptosis during development

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe how deregulated apoptosis causes disease:

A

Too much or too little apoptosis can be catastrophic.
Too much apoptosis contributes to neurodegerative disorders e.g. Alzheimer’s disease where nerve cells die by an apoptotic mechanism.
Not enough apoptosis can lead to cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the basics of how apoptosis works:

A

Death signals activate caspase enzymes.

Caspases dismantle the cell and generate the calssical apoptotic morphology.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe caspase enzymes:

A

Family of 14 cysteine aspartate-specific proteases that have a cysteine residue in the active site and cleave target proteins after an aspartate residue.
Exist in cells as inactive pro-enzymes or zymogens.
Activated by cleavage in response to specific cell stressors leading to cell suicide by apoptosis.
Caspases 2, 3, 6-10 as involved in apoptosis (the rest inflammation).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the discovery of the caspase enzymes:

A

Discovered based on homology with CED-3 in the nematode C.elegans. Cell number is precisely regulated in C.elegans. Blocking CED-3 prevents cells from dying.
Caspase-3 is the mammalian equivalent which promotes apoptotic death. KO mice have bigger brains and can’t prune down neurons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the pathways of caspase activation:

A

2 main pathways:
1. Extrinsic/death receptor pathway
2. Intrinsic/mitochondrial pathway
Also a third pathway involving the ER

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the extrinsic death receptor pathway:

A

Fas ligand binds to cell surface death receptor
Receptor association and recruitment of cytosolic adaptor protein FADD through death domain
DED of FADD binds to DED of procaspase-8 (or 10)
Cleavage and activation of caspase-8
Cleavage and activation of caspase-3,6,7
Cleavage of caspase substrates and generation of apoptotic morphology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the intrinsic mitochondria pathway:

A

Response to DNA damage and p53 activation
Cytochrome c released into cytoplasm
Interaction of cytochrome c, Apar-1 and procaspase-9 to form the apoptosome
Cleavage and activation of caspase-9
Cleavage and activation of caspase-3,6,7
Cleavage of caspase substrates and generation of apoptotic morphology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the endoplasmic reticulum pathway:

A

Response to protein misfolding and ER stress
Cleavage and activation of caspase-12
Cleavage and activation of caspase-9 followed by caspases-3,6,7
Cleavage of caspase substrates and generation of apoptotic morphology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe caspase substrates:

A

Caspase mediated cleavage of:

  1. PARP inactivates DNA repair
  2. ICAD allows nuclear translocation of CAD and internucleosomal DNA fragmentation
  3. Lamins results in nuclear shrinkage
  4. Fodrin and Actin results in reorganisation of the cytoskeleton
  5. Bid by caspase 8 through the death receptor pathway allows mitochondrial release of cytochrome c and activation of mitochondrial apoptotic pathway
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe caspase-independent apoptosis:

A

Cells grown in culture undergo apoptosis in the presence of pan caspase inhibitor Z-VAD.fmk.
This suggests caspase-independent mechanisms which also lead to apoptotic cell death, such as necroptosis, a regulated form of necrotic death.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the role of anti-apoptotic molecules:

A

Prevent unwanted caspase activation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe anti-apoptotic molecules in the mitochondrial pathway:

A

Bcl-2 and Bcl-XI prevent cytochrome c release. Inhibit channel formation in the outer membrane by sequestering pore-forming pro-apoptotic proteins e.g. Bax and Bak.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Describe anti-apoptotic molecules in the death receptor pathway:

A

FLIP family contain DED regions and compete with caspase-8 and 10 for binding to death receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe the inhibitors of apoptosis proteins (IAPs):

A

Endogenous caspase inhibitors (XIAP, NIAP, cIAP-1, cIAP-2, livin, survivin).
Bind to active caspase enzymes (3,7,9). Prevent substrate entry into caspase active site and promote ubiquitination and proteasomal degradation. Inhibited by Smac/DIABLO released from mitochondria intermembrane space with cytochrome c. Therefore apoptosis is regulated by activation of death proteins (caspases) and inactivation of survival proteins.

20
Q

Describe brain damage:

A

Nerve cell death.
Results from acute (trauma, stroke, concussion) or chronic (neurodegenerative) injuries.
Injury disrupts normal glutamate neurotransmission.

21
Q

Define excitotoxicity:

A

Prolonged or excessive activation of glutamate receptors kills neurons.

22
Q

Describe the normal functions of glutamate:

A

Main excitotory neurotransmitter in the brain, diverse functions including learning, memory, movement and sensation.

23
Q

Describe the types of glutamate receptors:

A

Iontropic (NMDA and AMPA/Kainate)

Metabotrophic (I, II, III)

24
Q

Describe the action of NMDA receptors:

A

Depolarisation (remove Mg2+) + glutamate + glycine (agonists)
Opens channel (permeable to calcium)
Influx of calcium
Depolarisation of neuron

25
Describe the AMPA/Kainate receptors:
Glutamate binds Opens channel Influx of Na+ (+GluR2) or Ca2+ (-GluR2) Depolarisation of neuron
26
Describe the significance of GluR2 subunit:
GluR2 is involved in mRNA editing, where 1 amino acid change occurs in the channel pore, leading to a positive amino acid, which allows Na+ to pass through.
27
Describe the group I metabotrophic receptors:
mGluR1&5 Activate phospholipase C and depolarise neurons Antagonists are neuroprotective in model systems Glutamate increases IP3/DAG, resulting in increase of calcium from intracellular stores and increased protein kinase C.
28
Describe the group II metabotrophic receptors:
mGluR2&3 Gi-linked (inhibit adenylate cyclase) and cause presynaptic depression Agonists are neuroprotective by: Inhibiting neurotransmitter (glutamate) release and activating the production of neuroprotective molecules by astrocytes
29
Describe how glutamate kills neurons:
Injury Excitatory amino acids, greatly increased glutamate Pathological activation of glutamate receptors: NMDA- increased calcium- delayed (hours to days) nerve cells death leading to apoptosis AMPA- increased sodium, chloride, water- rapid (mins) nerve cell death leading to cell lysis (necrosis)
30
Describe the ratio of necrotic to apoptotic cell death due to glutamate excitotoxicity:
Higher concentrations of glutamate lead to increased necrotic cell death.
31
Describe how intracellular calcium can lead to excitotoxicity via activation of calcium-sensitive enzymes:
Lipases cause membrane damage Nucleases cause nuclear damage NOS cause ROS release Proteases cleave proteins
32
Describe how intracellular calcium can lead to excitotoxicity via mitochondrial damage:
Mitochondrial damage allows calcium to move in to the mitochondria and disrupt the electron transport chain thus no ATP produced. ROS are released causing damage. Cytochrome C is released and mitochondrial caspases are activated. Energy failure and caspase activation occurs.
33
Describe the relationship between excitotoxicity and stroke:
Excitotoxicity is thought to contribute to nerve cell death from acute injuries such as a stroke.
34
Define stroke:
Nerve cell death resulting from interruption of blood suppl y to the brain.
35
Describe how a stroke may lead to excitotoxicity:
Occlusion or obstruction of cerebral blood flow Deficient oxygen and glucose supply to neuronal tissue downstream ATP depletion (cell falls apart) Failure ATP-dependent Na+/K+ membrane pumps and Na+/Ca2+ exchanger Loss of normal ionic membrane gradients: 1. Weak excitotoxicity pathway 2. Classical excitotoxicity pathway Increased activation of glutamate receptors Increased Ca2+/Na+/Cl-/H2O Over-activation of Ca2+-dependent enzymes and cell swelling Excitotoxic nerve cell death
36
Describe the weak excitotoxicity pathway in stroke:
Loss of normal resting membrane potential | Depolarisation and loss of Mg2+ block from NMDA receptors
37
Describe the classical excitotoxicity pathway in a stroke:
Impaired function of Na+-dependent glutamate transporters | Impaired removal of glutamate from synapse
38
Describe amyotrophic lateral sclerosis (ALS)/Motorneuron disease:
Adult onset chronic neurodegenerative disorder Selective degeneration of motor neurons Muscle wasting, weakness, spasticity, paralysis Fate often due to respiratory muscle paralysis (on ventilators, die due to some type of infection) 2-5 years survival time (rapid degeneration)
39
Describe the causes of ALS:
Cu2+/Zn2+ superoxide dismutase (degrades ROS) mutation causes very small % of inherited cases Some sporadic cases associated with decreased expression of glutamate transporter in spinal cord and motor cortex Astrocytic excitotoxicity amino acid transporter 2 (EAAT2) removes glutamte from synapse for recycling
40
Describe how excitotoxicity may cause ALS:
Loss of astrocytic EAAT 2 in motor cortex and spinal cord Increased glutamate in synapse Over-activation of neuronal NMDA (increased Ca2+) and AMPA (increased Na+/Cl-/H2O) Death of motor neurons Symptoms of ALS
41
Describe some of the causes of ALS:
Calcium permeable AMPA receptors also more common in motor neurons of ALS suffers Defective mRNA editing of GluR2 subunit Motor neurons also less able to buffer changes in intracellular calcium
42
Describe how reducing glutamate release may treat ALS:
A1 adenosine receptor agonists (neuroprotective) Group II metabotrophic agonists (neuroprotective) Riluzole, treat ALS, acts presynaptically to inhibit glutamate release. Blocks sodium channels and desensitise neurons to depolarising stimuli, thereby inhibiting neurotransmitter release.
43
Describe how blocking NMDA receptors may treat ALS:
Open channel blockers such as MK801 and Memantine- focal ischaemia (strokes) and status epilepticus BUT have neuropsychiatric side-effects (psychosis) and impair learning and memory. A troke trial of competitive NMDA antagonist Selfotel was terminated due to safety concerns. Glycine site blockers such as Gavestinel are better tolerated but have shown no therapeutic benefit in human stroke trials.
44
Describe non-NMDA receptors for treating ALS:
AMPA/Kainate antagonists - NBQX Very effective against global ischaemia (up to 24 hours post ischaemic attack) and focal ischaemia (NMDA blockers not effective against global ischaemia). Side effect is nephrotoxicity Metabotropic receptors Group I antagonists and group II and III agonists are neuroprotective in model systems presynaptically.
45
Describe how blocking the intracellular cascade can treat ALS:
Inhibit the intracellular cascade triggered by glutamate receptor activated increased intracellular calcium. ROS, anti-oxidants, need the right models.